Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifampin vs Isoniazid for Latent TB in DM2
NCT03278483Phase 4Completed
- Sponsor
- Instituto Nacional de Salud Pública
- Start
- Feb 2019
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rifampicin in Tuberculosis (TB) (2 arms), sponsored by Instituto Nacional de Salud Pública. Primary endpoints: Efficacy of treatment with rifampicin compared to efficacy of treatment with isoniazid at 18 months, Toxicity (neuropathy) at 6 months and 2 more. Started Feb 2019; status: completed.
02
Drugs
rifampicin
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03278483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03278483.